Kisqali for HR-positive, HER2-negative advanced or metastatic breast cancer
Quick answer: Kisqali is used for HR-positive, HER2-negative advanced or metastatic breast cancer as part of a cdk4/6 inhibitor treatment regimen. Ribociclib inhibits cyclin-dependent kinases 4 and 6, halting tumor cell-cycle progression at G1/S The specific dosing for HR-positive, HER2-negative advanced or metastatic breast cancer is determined by your prescriber based on individual factors.
Why is Kisqali used for HR-positive, HER2-negative advanced or metastatic breast cancer?
Kisqali belongs to the CDK4/6 inhibitor class. Ribociclib inhibits cyclin-dependent kinases 4 and 6, halting tumor cell-cycle progression at G1/S This action makes it useful for treating or managing HR-positive, HER2-negative advanced or metastatic breast cancer in patients for whom this approach is clinically appropriate.
It is one of several treatment options. Whether Kisqali is the right choice for a specific patient depends on the type and severity of HR-positive, HER2-negative advanced or metastatic breast cancer, response to previous treatments, individual risk factors, and clinical guidelines.
Typical dosing for HR-positive, HER2-negative advanced or metastatic breast cancer
Common adult dosing range: 600 mg orally once daily, 3 weeks on / 1 week off. The actual dose for HR-positive, HER2-negative advanced or metastatic breast cancer depends on:
- Severity of the condition
- Patient's age, weight, and organ function
- Other medications being taken
- Treatment response and tolerability
For complete dosing details, see the Kisqali medicine page.
What to expect
Kisqali treatment for HR-positive, HER2-negative advanced or metastatic breast cancer typically involves:
- Onset of effect: varies by indication and dose — some effects are immediate, others take days to weeks
- Treatment duration: some courses are short-term, others are long-term or lifelong depending on HR-positive, HER2-negative advanced or metastatic breast cancer
- Monitoring: follow-up visits to assess response and adjust dosing
- Side-effect awareness: learning what to expect and what warrants medical attention
Alternatives to consider
If Kisqali is not appropriate or not tolerated, alternatives within the same class or different therapeutic classes may be considered. See all CDK4/6 inhibitor for related options.
When to talk to your doctor
Discuss with your prescriber if you experience:
- Inadequate symptom control on Kisqali
- Side effects affecting daily life
- New medications or supplements that may interact
- Pregnancy planning or pregnancy
- Major changes in health status
Related information
Kisqali full prescribing information · All CDK4/6 inhibitor alternatives
Frequently asked questions
How effective is Kisqali for HR-positive, HER2-negative advanced or metastatic breast cancer?
Effectiveness varies by individual response, dose, and severity. Kisqali is one of several treatment options for HR-positive, HER2-negative advanced or metastatic breast cancer, supported by clinical evidence within the cdk4/6 inhibitor class. Discuss expected response with your prescriber.
How long do I need to take Kisqali for HR-positive, HER2-negative advanced or metastatic breast cancer?
Treatment duration depends on the nature of HR-positive, HER2-negative advanced or metastatic breast cancer — some treatments are short-term, others long-term or lifelong. Never stop on your own; discontinuation requires clinical guidance to avoid relapse or rebound effects.
What are the main side effects of Kisqali when used for HR-positive, HER2-negative advanced or metastatic breast cancer?
Common and serious side effects are class-related and substance-specific. See the full medicine page for the complete profile. Report any unexpected effects to your prescriber.
Are there alternatives to Kisqali for HR-positive, HER2-negative advanced or metastatic breast cancer?
Yes. Multiple medicines and non-drug options exist for HR-positive, HER2-negative advanced or metastatic breast cancer. Alternatives within the cdk4/6 inhibitor class share mechanisms; other classes may offer different approaches. Discuss with your clinician.
Last reviewed: by iMedic Medical Editorial Team. Our editorial process.